Show simple item record

dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorMerry, Catherine L R
dc.contributor.authorDavies, E June
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2009-10-13T10:45:37Z
dc.date.available2009-10-13T10:45:37Z
dc.date.issued2001-10-19
dc.identifier.citationHeparan sulfate proteoglycans and cancer. 2001, 85 (8):1094-8 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid11710818
dc.identifier.doi10.1054/bjoc.2001.2054
dc.identifier.urihttp://hdl.handle.net/10541/84147
dc.description.abstractHeparan sulfate proteoglycans (HSPGs) are widely distributed in mammalian tissues and involved in a number of processes related to malignancy. They are composed of a core protein to which chains of the glycosaminoglycan, heparan sulfate (HS), are attached. The existence of various classes of core protein, in addition to highly polymorphic HS chains, creates a superfamily of macromolecules with considerable diversity of structure and function. HSPGs interact with many proteins including growth factors, chemokines and structural proteins of the extracellular matrix to influence cell growth, differentiation, and the cellular response to the environment. The recent identification of two inherited syndromes that are associated with an increased cancer risk, and caused by mutations in HSPG-related genes, has intensified interest in these molecules. This review describes our current understanding of HSPGs in cancer and highlights new possibilities for therapeutic control.
dc.language.isoenen
dc.subjectCanceren
dc.subjectCancer Invasivenessen
dc.subject.meshAnimals
dc.subject.meshCell Division
dc.subject.meshGlucuronidase
dc.subject.meshGlycosylation
dc.subject.meshGlypicans
dc.subject.meshHeparan Sulfate Proteoglycans
dc.subject.meshHeparitin Sulfate
dc.subject.meshHumans
dc.subject.meshNeoplasm Invasiveness
dc.subject.meshNeoplasms
dc.subject.meshNeovascularization, Pathologic
dc.titleHeparan sulfate proteoglycans and cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Medical Oncology, Christie Hospital and Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester, M20 4BX, UK.en
dc.identifier.journalBritish Journal of Canceren
refterms.dateFOA2020-04-22T12:16:42Z
html.description.abstractHeparan sulfate proteoglycans (HSPGs) are widely distributed in mammalian tissues and involved in a number of processes related to malignancy. They are composed of a core protein to which chains of the glycosaminoglycan, heparan sulfate (HS), are attached. The existence of various classes of core protein, in addition to highly polymorphic HS chains, creates a superfamily of macromolecules with considerable diversity of structure and function. HSPGs interact with many proteins including growth factors, chemokines and structural proteins of the extracellular matrix to influence cell growth, differentiation, and the cellular response to the environment. The recent identification of two inherited syndromes that are associated with an increased cancer risk, and caused by mutations in HSPG-related genes, has intensified interest in these molecules. This review describes our current understanding of HSPGs in cancer and highlights new possibilities for therapeutic control.


Files in this item

Thumbnail
Name:
89180.pdf
Size:
238.3Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record